{"entity":{"id":"nct06262139","kind":"trial","name":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","aka":[],"tldr":"A phase 1/2 trial of MT218 injection in prostate cancer, run by Songqi Gao, now recruiting.","summary":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients is a phase 1/2 interventional study registered as NCT06262139 by Songqi Gao, with 12 participants planned, started 2024-07-25 and due to reach its primary completion in 2026-12. Interventions recorded: MT218 injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06262139","url":"https://clinicaltrials.gov/study/NCT06262139"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06262139","phase":"1/2","setting":"An Open-label Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent (MT218) in Prostate Cancer Patients","sponsor":"Songqi Gao","enrolled":12,"outcomes":[]},"route":"/trials/nct06262139/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}